Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised placebo-controlled trial

John R. Teerlink, Gad Cotter, Beth A. Davison, G. Michael Felker, Gerasimos Filippatos, Barry H. Greenberg, Piotr Ponikowski, Elaine Unemori, Adriaan A. Voors, Kirkwood F. Adams, Maria I. Dorobantu, Liliana R. Grinfeld, Guillaume Jondeau, Alon Marmor, Josep Masip, Peter S. Pang, Karl Werdan, Sam L. Teichman, Angelo Trapani, Christopher A. BushRajnish Saini, Christoph Schumacher, Thomas M. Severin, Marco Metra

Research output: Contribution to journalArticle

650 Scopus citations


Background Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many biological and haemodynamic eff ects. In a pilot study, serelaxin was safe and well tolerated with positive clinical outcome signals in patients with acute heart failure. The RELAX-AHF trial tested the hypothesis that serelaxin-treated patients would have greater dyspnoea relief compared with patients treated with standard care and placebo. Methods RELAX-AHF was an international, double-blind, placebo-controlled trial, enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via a central randomisation scheme blocked by study centre to standard care plus 48-h intravenous infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation. All patients had dyspnoea, congestion on chest radiograph, increased brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, mild-to-moderate renal insuffi ciency, and systolic blood pressure greater than 125 mm Hg. Patients, personnel administering study drug, and those undertaking study-related assessments were masked to treatment assignment. The primary endpoints evaluating dyspnoea improvement were change from baseline in the visual analogue scale area under the curve (VAS AUC) to day 5 and the proportion of patients with moderate or marked dyspnoea improvement measured by Likert scale during the fi rst 24 h, both analysed by intention to treat. This trial is registered at, NCT00520806. Findings 1161 patients were randomly assigned to serelaxin (n=581) or placebo (n=580). Serelaxin improved the VAS AUC primary dyspnoea endpoint (448 mm × h, 95% CI 120-775; p=0·007) compared with placebo, but had no signifi cant eff ect on the other primary endpoint (Likert scale; placebo, 150 patients [26%]; serelaxin, 156 [27%]; p=0·70). No signifi cant eff ects were recorded for the secondary endpoints of cardiovascular death or readmission to hospital for heart failure or renal failure (placebo, 75 events [60-day Kaplan-Meier estimate, 13·0%]; serelaxin, 76 events [13·2%]; hazard ratio [HR] 1·02 [0·74-1·41], p=0·89] or days alive out of the hospital up to day 60 (placebo, 47·7 [SD 12·1] days; serelaxin, 48·3 [11·6]; p=0·37). Serelaxin treatment was associated with signifi cant reductions of other prespecifi ed additional endpoints, including fewer deaths at day 180 (placebo, 65 deaths; serelaxin, 42; HR 0·63, 95% CI 0·42-0·93; p=0·019). Interpretation Treatment of acute heart failure with serelaxin was associated with dyspnoea relief and improvement in other clinical outcomes, but had no eff ect on readmission to hospital. Serelaxin treatment was well tolerated and safe, supported by the reduced 180-day mortality. Funding Corthera, a Novartis affi liate company.

Original languageEnglish (US)
Pages (from-to)29-39
Number of pages11
JournalThe Lancet
Issue number9860
StatePublished - Jan 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., Ponikowski, P., Unemori, E., Voors, A. A., Adams, K. F., Dorobantu, M. I., Grinfeld, L. R., Jondeau, G., Marmor, A., Masip, J., Pang, P. S., Werdan, K., Teichman, S. L., Trapani, A., ... Metra, M. (2013). Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised placebo-controlled trial. The Lancet, 381(9860), 29-39.